Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative

Autor: Nielsen, S.M., Tugwell, P., Wit, M.P.T. de, Boers, M., Beaton, D.E., Woodworth, T.G., Escorpizo, R., Shea, B., Toupin-April, K., Guillemin, F., Strand, V., Singh, J.A., Kloppenburg, M., Furst, D.E., Wells, G.A., Smolen, J.S., Vesely, R., Boonen, A., Storgaard, H., Voshaar, M., March, L., Christensen, R., Contextual Factors Working Grp

Publikováno v: Journal of Rheumatology
Journal of Rheumatology, Journal of Rheumatology Publishing Company Limited, 2019, 46 (9), pp.1159-1163. ⟨10.3899/jrheum.181081⟩
Journal of Rheumatology, 46(9), 1159-1163. Journal of Rheumatology Publishing Co. Ltd.
Journal of Rheumatology, 46(9), 1159-1163
Journal of Rheumatology, 46(9), 1159-1163. Journal of Rheumatology
Nielsen, S M, Tugwell, P, de Wit, M P T, Boers, M, Beaton, D E, Woodworth, T G, Escorpizo, R, Shea, B, Toupin-April, K, Guillemin, F, Strand, V, Singh, J A, Kloppenburg, M, Furst, D E, Wells, G A, Smolen, J S, Veselý, R, Boonen, A, Storgaard, H, Voshaar, M, March, L & Christensen, R 2019, ' Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology : Results from an OMERACT Initiative ', Journal of Rheumatology, vol. 46, no. 9, pp. 1159-1163 . https://doi.org/10.3899/jrheum.181081
Journal of rheumatology, 46(9), 1159-1163. Journal of Rheumatology
Nielsen, S M, Tugwell, P, De Wit, M P T, Boers, M, Beaton, D E, Woodworth, T G, Escorpizo, R, Shea, B, Toupin-April, K, Guillemin, F, Strand, V, Singh, J A, Kloppenburg, M, Furst, D E, Wells, G A, Smolen, J S, Veselý, R, Boonen, A, Storgaard, H, Voshaar, M, March, L, Christensen, R & for the Contextual Factors Working Group 2019, ' Identifying provisional generic contextual factor domains for clinical trials in rheumatology : Results from an OMERACT initiative ', Journal of Rheumatology, vol. 46, no. 9, pp. 1159-1163 . https://doi.org/10.3899/jrheum.181081

Objective.The Contextual Factors Working Group aims to provide guidance on addressing contextual factors in rheumatology trials within OMERACT.Methods.During the Special Interest Group session at OMERACT 2018, preliminary results were presented from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5810d552e1fd11d936ba640060aae324
https://hal.univ-lorraine.fr/hal-02007495

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Autor: Alten, R., Gram, H., Joosten, L.A.B., Berg, W.B. van den, Sieper, J., Wassenberg, S., Burmester, G.R., Riel, P.L.C.M. van, Diaz-Lorente, M., Bruin, G.J., Woodworth, T.G., Rordorf, C., Batard, Y., Wright, A.M., Jung, T.

Publikováno v: Arthritis Research & Therapy, 10, 3, pp. R67-R67
Arthritis Research & Therapy, 10, R67-R67

Contains fulltext : 70732.pdf (Publisher’s version ) (Open Access) INTRODUCTION: IL-1beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. METHODS:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7d95e3ddfb4b6d93f2388784587a937f
https://hdl.handle.net/2066/70732

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.